Amphoteric fluorescent substances that can be linked to biological materials

An amphoteric fluorescent substance with zwitterionic properties addresses non-specific binding issues, enhancing the accuracy of protein detection and analysis by stabilizing in buffer solutions and reducing false positive reactions.

JP7587292B2Active Publication Date: 2024-11-20C BIOMEX CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2022548531
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-02-10
Publication Date
2024-11-20
Estimated Expiration
2040-02-10

AI Technical Summary

Technical Problem

Existing fluorescent dyes with strong aromatic and hydrophobic properties cause non-specific binding to proteins and biomolecules, leading to false positive reactions and decreased reliability in immunochemical diagnosis and biochip utilization.

Method used

Development of an amphoteric fluorescent substance with a zwitterionic moiety that minimizes non-specific reactions by incorporating a pentamethine cyanine dye with a pair of zwitterion moieties and specific linkers, such as -Ph-CH2-C(=O)-L, enhancing stability and specificity in buffer solutions.

Benefits of technology

The amphoteric fluorescent substance reduces non-specific binding, improving the accuracy of protein detection and analysis by maintaining fluorescence intensity and structural stability in aqueous solutions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007587292000017
    Figure 0007587292000017
  • Figure 0007587292000001
    Figure 0007587292000001
  • Figure 0007587292000002
    Figure 0007587292000002
Patent Text Reader

Abstract

Provided are amphoteric fluorescent substances that can be linked to biological materials. The present invention relates to a compound containing at least one compound represented by the following structural formula 1: It is an amphoteric fluorescent substance that can be linked to biological materials. <Structural formula 1> [C24] TIFF2023513285000025.tif85161
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to amphoteric fluorescent substances which can be linked to biological materials. [Background technology]

[0002] Fluorescent dyes have been widely used in biological research and recently have been utilized not only in clinical diagnosis (immunochemistry, molecular diagnosis, etc.) but also in specialized surgical procedures such as cancer treatment.

[0003] Fluorescent dyes have been used in microarray technology and cell analysis research related to omics, and more recently, they have also been used in molecular biology research, such as western blot and real-time PCR.

[0004] Fluorescent dyes are widely used in a wide range of applications, from traditional immunochemical diagnostics to the recently developed point of care testing (POCT) and molecular diagnostics (biosensors, etc.).

[0005] Recently, with the development of targeted therapeutic agents and associated diagnostic techniques, a technique has been developed that can confirm the extent of metastasis of cancer cells at the same time as cancer surgery using fluorescent dyes.

[0006] Most of the fluorescent dyes that have been developed and commercialized to date are charged, which induces non-specific binding with charged biological macromolecules such as proteins, nucleic acids, and lipids. Summary of the Invention [Problem to be solved by the invention]

[0007] Perfectly neutral fluorescent dyes, due to their strong aromaticity and hydrophobicity, show false positive reactions due to non-specific binding with proteins containing many aromatic amino acids and large hydrophobic biomolecules. These false positive reactions cause a decrease in the reliability of immunochemical diagnosis of protein-specific peptide techniques and the application of biochips.

[0008] Meanwhile, small biomolecules such as peptides and aptamers have a low molecular weight, and when they are bound to existing fluorescent dyes, they are governed by the charge characteristics of the fluorescent dyes.

[0009] In order to minimize non-specific binding between fluorescent dyes and biomolecules, methods such as using buffer solutions or neutral surfactants can be considered. Recently, however, fluorescent dyes have been used in biosensors and surgical procedures, and precision in analysis is required.

[0010] The present invention has been made to solve the problems of the prior art described above. The inventors developed fluorescent dyes as amphoteric substances, which are basic properties of amino acids and proteins, and focused on minimizing the non-specific reactivity of fluorescent dyes with biomolecules, thereby completing the present invention.

[0011] The problem to be solved by the present invention is to provide a novel fluorescent dye capable of improving the accuracy of protein detection and analysis.

[0012] The object of the present invention is not limited to the technical objects mentioned above, and other technical objects not mentioned can be clearly understood by those skilled in the art from the following description. [Means for solving the problem]

[0013] The amphoteric fluorescent substance capable of binding to a biological material according to the present invention includes at least one compound represented by the following structural formula 1:

[0014] <Structural formula 1> [ka]

[0015] In the above structural formula 1, L is -(L1) n -(L2).

[0016] In the above structural formula 1, L1 is -NH-CH2-(CH2-O-CH2) m -CH2-C(=O)-.

[0017] In the above structural formula 1, L2 is an azide, an acetylene, a maleimide, a biotin, a hydrazide, [ka] , -R3-(C(=O)2-NH-NH2, and -R4-(S(=O)2-NH-NH2; R 1 , R 2 , R3 and R4 are each a C1 to C6 divalent aliphatic hydrocarbon, a C1 to C6 alkylene or a divalent aromatic hydrocarbon.

[0018] In the above structural formula 1, n is 0 or 1.

[0019] In the above structural formula 1, m is a constant of 0 to 4.

[0020] Other specific details of the embodiments are contained in the detailed description and drawings. Effect of the Invention

[0021] The present invention has at least the following advantages:

[0022] The amphoteric fluorescent material according to the present invention can minimize non-specific reactions to biological materials and improve the accuracy of protein detection and analysis.

[0023] The effects of the present invention are not limited to the above-mentioned examples, and more diverse effects are included in the present specification. [Brief description of the drawings]

[0024] [Figure 1] 1 shows the results of UPLC (Ultra-Performance Liquid Chromatography) analysis of an amphoteric fluorescent material according to an embodiment of the present invention. BEST MODE FOR CARRYING OUT THEINVENTION

[0025] The advantages and features of the present invention, as well as the methods for achieving them, will become apparent from the following detailed description of the embodiments. The present invention is not limited to the embodiments disclosed below, but may be embodied in various different forms. However, the embodiments are provided to fully disclose the present invention and fully inform those skilled in the art of the scope of the invention, and the present invention is defined only by the scope of the claims.

[0026] In addition, in describing the technology disclosed in this specification, if a specific description of related publicly known technology is determined to obscure the gist of the technology disclosed in this specification, the detailed description will be omitted.

[0027] Throughout this specification, when a part is described as "comprising" or "having" a certain element, this does not mean to exclude other elements, but means that it can further include other elements, unless specifically stated to the contrary.

[0028] Furthermore, throughout this specification, "A to B" means a range of A or more and B or less, "A or more and less than B" means a range of A or more and less than B, and "more than A and B or less" means a range of more than A and B or less. In this specification, "Ca to b" means that the number of carbon atoms is a to b. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0029] The amphoteric fluorescent substance of the invention contains a zwitterionic moiety in which a cation and an anion coexist, and therefore can minimize non-specific reactions with biological substances such as amino acids, peptides, or proteins.

[0030] The amphoteric fluorescent substance capable of binding to a biological material according to the present invention (hereinafter referred to as the "amphoteric fluorescent substance of the present invention") includes at least one compound represented by the following structural formula 1.

[0031] <Structural formula 1> [ka]

[0032] The compound represented by the above structural formula 1 is a compound in which a zwitterion moiety that pairs with a pentamethine cyanine dye and -Ph-CH2-CH2-C(=O)-L are introduced as a linker that can be linked to a biological substance such as an amino acid, peptide, or protein. Ph is [ka] It is.

[0033] According to the inventors' findings, the control group, in which -O-Ph-CH2-CH2-C(=O)-L was introduced as a linker, had an unstable structure in a buffer aqueous solution, and when used to label biological materials such as proteins, the fluorescence intensity during screening weakened over time. On the other hand, the amphoteric fluorescent material of the invention, in which -Ph-CH2-CH2-C(=O)-L was introduced as a linker, had a higher structural stability in a buffer aqueous solution than the control group.

[0034] In the above structural formula 1, L is -(L1) n -(L2). L1 is -NH-CH2-(CH2-O-CH2) m-CH2-C(=O)-, and L2 is azide, acetylene, maleimide, biotin, hydrazide, [ka] , -R3-(C(=O)2-NH-NH2, and -R4-(S(=O)2-NH-NH2. R 1 , R 2 , R3 and R4 are each a C1 to C6 divalent aliphatic hydrocarbon, a C1 to C6 alkylene or a divalent aromatic hydrocarbon.

[0035] In the above structural formula 1, n is 0 or 1. When n is 0, -L in -Ph-CH2-CH2-C(=O)-L is -L2. When n is 1, -L in -Ph-CH2-CH2-C(=O)-L is -L1-L2.

[0036] In the above structural formula 1, m is a constant of 0 to 4. When m is 0, L1 is -NH-CH2-CH2-C(=O)-, when m is 1, L1 is -NH-CH2-CH2-O-CH2-CH2-C(=O)-, when m is 2, L1 is -NH-CH2-(CH2-O-CH2)-(CH2-O-CH2)-CH2-C(=O)-, when m is 3, L1 is -NH-CH2-(CH2-O-CH2)-(CH2-O-CH2)-(CH2-O-CH2)-CH2-C(=O)-, and when m is 4, L1 is -NH-CH2-(CH2-O-CH2)-(CH2-O-CH2)-(CH2-O-CH2)-(CH2-O-CH2)-(CH2-O-CH2)-CH2-C(=O)-.

[0037] The larger the value of m, the more the solubility of the amphoteric fluorescent substance of the present invention in an aqueous buffer solution increases, making labeling more effective, and the more the distance between the amphoteric fluorescent substance of the present invention and biological materials such as proteins can be increased, minimizing the effect of the amphoteric fluorescent substance of the present invention on biological materials such as proteins.

[0038] For example, the compound represented by the above structural formula 1 may be at least one of the compounds represented by the following structural formula 2.

[0039] <Structural formula 2> [ka]

[0040] In the above structural formula 2, L1 and n are as defined in the above structural formula 1.

[0041] For example, one of the compounds represented by the above structural formula 2 may be a compound represented by the following structural formula 3, or a compound represented by the following structural formula 4.

[0042] <Structural formula 3> [ka]

[0043] <Structural formula 4> [ka]

[0044] <Synthesis Example> The compound represented by structural formula 4 was synthesized according to the following synthesis scheme. [ka]

[0045] (E)-N-((Z)-2-Bromo-3-(phenylamino)allylidene)benzenaminium bromide(1).

[0046] Mucobromic acid (5.940 g, 23.04 mmol) was dissolved in ethanol (40 mL), and then aniline (4.286 g, 4.2 mL, 46.1 mmol) diluted in ethanol (20 mL) was added dropwise over 10 min.

[0047] The reaction vessel was stirred vigorously and heated gradually to 40°C. After the addition of aniline was complete, additional carbon dioxide (CO2) was produced indicating the reaction was not complete. After the evolution of carbon dioxide was complete, the golden-brown reaction mixture was frozen in an ice bath. Diethyl ether (50 mL) was added with stirring at low temperature until a light yellow solid precipitated. The solid was filtered, washed with ether, dried and used in the subsequent reaction without purification.

[0048] Yield 75%; Melting point (mp) 189℃~191℃; 1H NMR (400MHz, DMSO-d6): δ7.330(t, J=7.2Hz, 2H), 7.496(t, J=8Hz, 4H), 7.708(d, J=8Hz, 4H), 9.559(s, 2H), 11.513(s, 2H); 13C NMR (100MHz, DMSO-d6): d89.3, 119.5, 123.9, 126.0, 129.2, 129.6, 138.5, 157.4. [ka]

[0049] 2,3,3-Trimethyl-1-[3-(trimethylammonio)propyl]-3H-indolium-5-sulfonate dibromide(2).

[0050] A mixture of 2,3,3-trimethyl-3H-indole-5-sulfonic acid (7.17 g, 36.4 mmol) and (3-bromopropyl)trimethyl ammonium bromide (10.5 g, 40 mmol) in toluene (60 mL) was heated at 130° C. for 72 h under a nitrogen atmosphere. The mixture was cooled to room temperature and the solvent was poured off. The crude product was crystallized from methanol and MTBE to give pink crystals that were used in the subsequent step without further purification.

[0051] Yield: 81%; Melting point (mp): 232℃~235℃; 1H NMR (400MHz, DMSO-d6): δ1.56(s, 6H), 2.51(s, 3H), 3.07(m, 2H), 3.12(s, 9H), 3.62(t, J=7. 2Hz, 2H), 4.50(t, J=7.2Hz, 2H), 7.71(d, J=8.0Hz, 1H), 7.79(d, J=8.0Hz, 1H), 8.01(s, 1H). 13C NMR (100MHz, DMSO-d6): δ15.0, 21.6, 22.3, 45.2, 53.1, 55.0, 62.4, 115.4, 121.2, 126.8, 141.3, 142.0, 149.9, 199.1. C 17 H 27 HRMS (ESI) m / z calculated for N2O3S[M]+ 339.1740, observed m / z 339.1742. [ka]

[0052] 2-((1E,3Z)-3-bromo-5-((E)-3,3-dimethyl-5-sulfonato-1-(3-(trimethylammonio)propyl)indolin-2-ylid ene)penta-1,3-dien-1-yl)-3,3-dimethyl-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium-5-sulfonate bromide(3).

[0053] Substituted 2,3,3-trimethyl indolenine salts bearing N-heterocyclic quaternary ammonium moiety2 (2 mol eq) were reacted with brominated methine reagent 1 (1 mol eq) in the presence of acetic anhydride (8 mL) and sodium acetate (4 mol eq) at 70 °C.

[0054] The reaction was monitored using UV-Vis-NIR absorption spectroscopy in methanol and LC-MS. After 2-4 hours, the reaction was complete. The solvent was removed under vacuum. The crude material was purified using Fluka silica gel 90 Å C18 reverse phase chromatography using a gradient solvent composition of methanol and water to give the final compound in high purity.

[0055] Yield 77%; Melting point (mp) 252℃~254℃; 1HNMR (400MHz, DMSO-d6): δ2.05(s, 12H), 2.71(t, J=7.6Hz, 4H), 3. 47(s, 18H), 3.86(tt, J=7.6Hz, 7.2Hz, 4H), 4.64(t, J=7.2Hz, 4H), 6.78(d, J=13.2Hz, 2H), 7.73(d, J=8. 0Hz, 2H), 8.21(d, J=8Hz, 2H), 8.25(s, 2H), 8.56(d, J=13.2Hz, 2H);13CNMR(100MHz, DMSO-d6), δ:20.3 , 26.3, 40.6, 49.7, 52.3, 63.6, 103.0, 110.2, 116.4, 119.1, 126.6, 140.3, 141.3, 142.5, 150.6, 176.7. Theoretical composition: (x3H2O): C (47.95%), H (6.31%), N (6.05%); Actual composition: C (47.46%), H (6.48%), N (6.05%); [C 37 H 52 HRMS(ESI) m / z theoretical 792.8822 for BrN4O6S2]+, observed m / z 792.8854. [ka]

[0056] 3-(4-((1E,3Z,5E)-1-(3,3-dimethyl-5-sulfonato-1-(3-(trimethylammonio)propyl)-3H-indol-1-ium-2-yl)-5-(3,3-dim ethyl-5-sulfonato-1-(3-(trimethylammonio)propyl)indolin-2-ylidene)penta-1,3-dien-3-yl)phenyl)propanoate(5).

[0057] An aqueous solution of the bromo dye precursor 3 (1.0 mmol) and 3-(4-boronophenyl)propanoic acid 4 (1.8 mmol) was heated under reflux in the presence of Pd(PPh3)4 (0.065 mmol) for 72 h.

[0058] The reaction progress was monitored by visible / near infrared spectroscopy with an aliquot diluted in methanol until the absorption of bromorocyanine disappeared.

[0059] The reaction mixture was then frozen at room temperature and the H2O was removed under reduced pressure. The solid was isolated by precipitation with MeOH / acetone and the precipitate was further washed with acetone.

[0060] The final fluorescent material was obtained using open-reverse phase column chromatography (eluted with acetonitrile / water).

[0061] Yield 72%; Melting point (mp)>260℃; λmax=645nm in H2O; 1H NMR (DMSO-d6), δ: 1.78(s, 12H), 1.99(br s, 4H), 2.65(br s, 2H), 2.93(br s, 2H), 3.08(s, 18H), 3.25(br s, 4H), 3.84(br s, 4H), 5.65(d, J=7.0Hz, 2H), 7.27(d, J=3.8Hz, 2H), 7.35(d, J=4.2Hz, 2H), 7.42(d, J=4 .0Hz, 2H), 7.60(d, J=4.2Hz, 2H), 7.87(s, 1H), 8.54(d, J=7.0Hz, 2H), 12.33(s, 1H); 13C NMR (100MHz, D2O, 70℃), δ:21.16, 27.51, 32.25, 39.42, 41.30, 49.82, 53.84, 63.95, 102.87, 111.37, 120.49, 127.51, 129.92, 130.67, 133.25, 137.19, 141.23, 142.04, 143.57, 155.23, 175.21, 181.88; 46 H 60 HRMS (TOF MS ES+) m / z theoretical value for N4O8S2 was 860.3853 [M]+, and m / z actual value was 862.4038 [M+2H]+.

[0062] By introducing -NH-CH2-(CH2-O-CH2)4-CH2-C(=O)-NHS into compound 5, a compound represented by structural formula 4 was obtained.

[0063] <nhs> [ka]

[0064] <Structural formula 4> [ka]

[0065] FIG. 1 shows the results of UPLC (Ultra-Performance Liquid Chromatography) analysis of the compound represented by structural formula 4.

[0066] UPLC analysis UPLC: WATERS. Column: HSS C18 SB 1.8mm 2.1×50mm. Gradient: 5 to 50% methanol over 3 minutes.

[0067] Although the embodiments of the present invention have been described above, the present invention is not limited to the above embodiments, and can be manufactured in various different forms. Those skilled in the art will understand that the present invention can be embodied in other specific forms without changing the technical concept or essential features of the present invention. Therefore, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. Industrial Applicability

[0068] The invention provides amphoteric fluorescent materials that can be linked to biological materials.

[0069] The amphoteric fluorescent material includes at least one compound represented by the following structural formula 1:

[0070] <Structural formula 1> [ka]

[0071] In the above structural formula 1, L is as defined herein.< / nhs>

Claims

1. An amphoteric fluorescent substance capable of binding to a biological material, represented by the following structural formula 4. <Structural formula 4> 【Chemistry 23】

2. 2. A method for detecting a protein using the amphoteric fluorescent substance according to claim 1, comprising detecting the protein by specific binding to the amphoteric fluorescent substance.

3. 2. A method for analyzing a protein using the amphoteric fluorescent substance according to claim 1, comprising detecting the protein by specific binding to the amphoteric fluorescent substance, and analyzing the detected protein.

Citation Information

Patent Citations

  • Hydrophilic thiol-reactive cyanine dyes and conjugates with biomolecules for fluorescence diagnostics

    JP2006513293A

  • Fluorescence imaging using substituted cyanine dyes

    JP2012524153A